SACATM meeting
This article was originally published in The Rose Sheet
Executive Summary
The Peer Review Report, "The Use of In Vitro Basal Cytotoxicity Test Methods for Estimating Starting Doses for Acute Oral Systemic Toxicity Testing," will be reviewed and discussed during the Scientific Advisory Committee on Alternative Toxicological Methods teleconference taking place Aug. 3 from 1 p.m. to 4 p.m., committee announces. Panel Report includes section that addresses the "rationale for the use of in vitro neutral red uptake cytotoxicity test methods to predict starting doses for in vivo acute oral systemic toxicity testing" and a section on the accuracy of the 3T3 and NHK NRU test methods. During a May 23 meeting of the Interagency Coordinating Committee on the Validation of Alternative Methods, a scientific peer review panel concluded the 3T3 and NHK methods are sufficient for use in a weight-of-evidence approach to determine the starting dose for acute oral in vivo toxicity testing (1"The Rose Sheet" May 29, 2006, p. 8)...
You may also be interested in...
ICCVAM Peer Review Meeting Evaluates Two In Vitro Cytotoxicity Tests
Two in vitro cytotoxicity test methods are sufficient for use in a weight-of-evidence approach to determine the starting dose for acute oral in vivo toxicity testing, a scientific peer review panel concluded by consensus during a meeting of the Interagency Coordinating Committee on the Validation of Alternative Methods in Bethesda, Md. May 23
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.